Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Account Payables (2016 - 2019)

Historic Change in Account Payables for Ultragenyx Pharmaceutical (RARE) over the last 4 years, with Q3 2019 value amounting to $3.9 million.

  • Ultragenyx Pharmaceutical's Change in Account Payables rose 29857.8% to $3.9 million in Q3 2019 from the same period last year, while for Sep 2019 it was $4.2 million, marking a year-over-year increase of 51767.03%. This contributed to the annual value of $3.4 million for FY2018, which is 251.52% down from last year.
  • As of Q3 2019, Ultragenyx Pharmaceutical's Change in Account Payables stood at $3.9 million, which was up 29857.8% from -$3.5 million recorded in Q2 2019.
  • In the past 5 years, Ultragenyx Pharmaceutical's Change in Account Payables ranged from a high of $4.0 million in Q4 2018 and a low of -$3.5 million during Q2 2019
  • Its 4-year average for Change in Account Payables is $639933.3, with a median of $187000.0 in 2016.
  • Examining YoY changes over the last 5 years, Ultragenyx Pharmaceutical's Change in Account Payables showed a top increase of 169893.05% in 2017 and a maximum decrease of 34326.45% in 2017.
  • Ultragenyx Pharmaceutical's Change in Account Payables (Quarter) stood at -$1.3 million in 2016, then soared by 68.66% to -$420000.0 in 2017, then skyrocketed by 1044.05% to $4.0 million in 2018, then decreased by 1.39% to $3.9 million in 2019.
  • Its Change in Account Payables stands at $3.9 million for Q3 2019, versus -$3.5 million for Q2 2019 and -$151000.0 for Q1 2019.